STAT Plus: Beyond the headline: Mirati undersells concerning data on its lung cancer immunotherapy
WIKIMEDIA COMMONS
The biotech chose to highlight the positive news in its update to investors. The details, disclosed for the first time, are far more concerning.
No hay comentarios:
Publicar un comentario